MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The inspection concluded with the issuance of a form 483 with five observations
Potential of Ayurveda’s contribution in global health system through various innovative practices
India has taken the lead in recognising NAFLD as a major non-communicable disease
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Subscribe To Our Newsletter & Stay Updated
